血塞通与依达拉奉联合治疗脑梗死患者的临床效果  

Clinical efficacy of Xuesaitong combined with Edaravone in the treatment of cerebral infarction patients

作　　者：汪丰华 WANG Fenghua(Department of Neurology,Caoxian People's Hospital,Heze,Shandong 274400,China)

机构地区：[1]曹县人民医院神经内科,山东菏泽274400

出　　处：《医药前沿》2025年第10期96-98,101,共4页Journal of Frontiers of Medicine

摘　　要：目的探讨脑梗死患者应用血塞通与依达拉奉联合治疗的临床效果。方法选取曹县人民医院神经内科2021年4月—2023年4月收治的90例脑梗死患者,采用随机数字表法分为观察组和对照组,每组45例。对照组接受依达拉奉单独治疗,观察组接受血塞通与依达拉奉联合治疗,比较两组临床疗效、各量表评分[美国国立卫生研究院卒中量表(NIHSS)、改良Rankin量表(MRS)、改良Barthel指数(MBI)]、炎症因子水平[肿瘤坏死因子-α(TNF-α)、白细胞介素-10(IL-10)、白细胞介素-6(IL-6)]、不良反应总发生率。结果治疗后,观察组临床总有效率和MBI评分高于对照组,NIHSS评分、MRS评分、TNF-α、IL-10、IL-6低于对照组,差异有统计学意义(P<0.05)。治疗期间,两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论采取血塞通与依达拉奉联合治疗脑梗死患者,有助于提升临床效果,改善各临床指标,且不会增加不良反应,具有较高安全性。Objective To investigate the clinical efficacy of Xuesaitong combined with Edaravone in the treatment of patients with cerebral infarction.Methods A total of 90 cerebral infarction patients admitted to the Department of Neurology at Caoxian People's Hospital from April 2021 to April 2023 were selected and divided into an observation group and a control group using a random number table method,with 45 patients in each group.The control group received Edaravone monotherapy,while the observation group received combined treatment with Xuesaitong and Edaravone.The clinical efficacy,scale scores[National Institutes of Health Stroke Scale(NIHSS),Modified Rankin Scale(MRS),Modified Barthel Index(MBI)],inflammatory factor levels[tumor necrosis factor-α(TNF-α),interleukin-10(IL-10),interleukin-6(IL-6)],and the total incidence of adverse reactions were compared between the two groups.Results After treatment,the total clinical effective rate and MBI score of the observation group were higher than those of the control group,and the NIHSS score,MRS score,TNF-α,IL-10 and IL-6 were lower than those of the control group,the differences were statistically significant(P<0.05).During the treatment,there was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusions The combination of Xuesaitong and Edaravone in the treatment of cerebral infarction patients can improve clinical efficacy,enhance clinical indicators,and does not increase the adverse reactions,demonstrating high safety.

关 键 词：脑梗死 血塞通 依达拉奉 美国国立卫生研究院卒中量表 改良Rankin量表 肿瘤坏死因子-Α 不良反应 

分 类 号：R743[医药卫生—神经病学与精神病学]